Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1

被引:509
作者
McQuibban, GA
Butler, GS
Gong, JH
Bendall, L
Power, C
Clark-Lewis, I
Overall, CM
机构
[1] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada
[2] Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada
[3] Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada
[4] Univ Sydney, Westmead Inst Canc Res, Sydney, NSW 2145, Australia
[5] Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada
关键词
D O I
10.1074/jbc.M107736200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chemokines provide directional cues for leukocyte migration and activation that are essential for normal leukocytic trafficking and for host responses during processes such as inflammation, infection, and cancer. Recently we reported that matrix metalloproteinases (MMPs) modulate the activity of the CC chemokine monocyte chemoattractant protein-3 by selective proteolysis to release the N-terminal tetrapeptide. Here we report the N-terminal processing, also at position 4-5, of the CXC chemokines stromal cell-derived factor (SDF)-1 alpha and beta by MMP-2 (gelatinase A). Robustness of the MMP family for chemokine cleavage was revealed from identical cleavage site specificity of MMPs 1, 3, 9, 13, and 14 (MT1-MMP) toward SDF-1; selectivity was indicated by absence of cleavage by AMP's 7 and 8. Efficient cleavage of SDF-1 alpha by MMP-2 is the result of a strong interaction with the NMP hemopexin C domain at an exosite that overlaps the monocyte chemoattractant protein-3 binding site. The association of SDF-1 alpha with different glycosaminoglycans did not inhibit cleavage. MMP cleavage of SDF-1 alpha resulted in loss of binding to its cognate receptor CXCR-4. This was reflected in a loss of chemoattractant activity for CD34(+) hematopoietic progenitor stem cells and pre-B cells, and unlike full-length SDF-1 alpha, the MMP-cleaved chemokine was unable to block CXCR-4-dependent human immunodeficiency virus-1 infection of CD4(+) cells. These data suggest that MMPs may be important regulatory proteases in attenuating SDF-1 function and point to a deep convergence of two important networks, chemokines and MMPs, to regulate leukocytic activity in vivo.
引用
收藏
页码:43503 / 43508
页数:6
相关论文
共 54 条
[1]   Stromal cell-derived factor-1α associates with heparan sulfates through the first β-strand of the chemokine [J].
Amara, A ;
Lorthioir, O ;
Valenzuela, A ;
Magerus, A ;
Thelen, M ;
Montes, M ;
Virelizier, JL ;
Delepierre, M ;
Baleux, F ;
Lortat-Jacob, H ;
Arenzana-Seisdedos, F .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (34) :23916-23925
[2]   Chemokines and leukocyte traffic [J].
Baggiolini, M .
NATURE, 1998, 392 (6676) :565-568
[3]   Antibodies to CD44 enhance adhesion of normal CD34(+) cells and acute myeloblastic but not lymphoblastic leukaemia cells to bone marrow stroma [J].
Bendall, LJ ;
Kirkness, J ;
Hutchinson, A ;
Bianchi, A ;
Makrynikola, V ;
Bradstock, KF ;
Gottlieb, DJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 98 (04) :828-837
[4]  
BENDALL LJ, 1993, BLOOD, V82, P3125
[5]  
Bigg HF, 2001, CANCER RES, V61, P3610
[6]   The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry [J].
Bleul, CC ;
Farzan, M ;
Choe, H ;
Parolin, C ;
ClarkLewis, I ;
Sodroski, J ;
Springer, TA .
NATURE, 1996, 382 (6594) :829-833
[7]   A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1) [J].
Bleul, CC ;
Fuhlbrigge, RC ;
Casasnovas, JM ;
Aiuti, A ;
Springer, TA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (03) :1101-1109
[8]  
ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233
[9]   Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1 [J].
Crump, MP ;
Gong, JH ;
Loetscher, P ;
Rajarathnam, K ;
Amara, A ;
Arenzana-Seisdedos, F ;
Virelizier, JL ;
Baggiolini, M ;
Sykes, BD ;
Clark-Lewis, I .
EMBO JOURNAL, 1997, 16 (23) :6996-7007
[10]  
Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO